Hookworm Infections Clinical Trial
— MoxipedOfficial title:
Efficacy and Safety of Moxidectin-albendazole Combination for Trichuris Trichiura Infections in School-aged Children: a Double-blind Randomised Controlled Superiority Trial
Verified date | June 2024 |
Source | Swiss Tropical & Public Health Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to albendazole monotherapy in school-aged children (SAC; aged 6-12 years) infected with whipworm (Trichuris trichiura) on Pemba Island, Tanzania. Additionally, evidence on the safety profile of moxidectin-albendazole combination in this age group will be substantiated using a placebo (and albendazole) only arm. To date, this has only been established in adolescents (aged 16-18 years), who might present different symptoms or symptom severity compared with SAC. As measure of efficacy of the treatment the cure rate (percentage of eggpositive subjects at baseline who become egg-negative after treatment) will be determined 14-21 days post-treatment.
Status | Active, not recruiting |
Enrollment | 210 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility | Inclusion Criteria: - individuals aged 6-12 years (confirmed by birth certificate or similar document) - having given written informed consent signed by parents/caregivers - being able and willing to provide two stool samples at baseline and at follow-up assessment (14-21 days) - having at least two out of four Kato-Katz slides positive for T. trichiura at baseline - being able and willing to be examined by a study physician before and after treatment Exclusion Criteria: - presence or signs of major systemic illness, e.g. fever (temporal body temperature of >38.0°C), severe anaemia (haemoglobin level of <80 g/l) - history of severe acute disease or unmanaged, severe chronic disease (i.e., condition is not as therapeutically controlled as necessary) - use of anthelminthic drugs during study period - known allergy to study medication (i.e., moxidectin or albendazole) - being prescribed or taking concomitantly medication with known contraindications or drug interactions with the study medication - pregnancy (female participants aged 10-12 years) - concurrent participation in other clinical trials |
Country | Name | City | State |
---|---|---|---|
Tanzania | Public Health Laboratory Ivo de Carneri | Chake Chake |
Lead Sponsor | Collaborator |
---|---|
Jennifer Keiser | Public Health Laboratory Ivo de Carneri |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Blood concentration of moxidectin | For characterization of population pharmacokinetics (PK), moxidectin concentration will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a lower limit of quantification of 1-5 ng/ml. | 0 to 24 hours post-treatment | |
Primary | Cure rate (CR) against T. trichiura | The CR will be calculated as the proportion of participants converting from being egg-positive pre-treatment to egg-negative post-treatment. | 14-21 days post-treatment | |
Secondary | Egg reduction rate (ERR) against T. trichiura | Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs. | 14-21 days post-treatment | |
Secondary | Cure rate (CR) against A. lumbricoides | The CR will be calculated as the proportion of participants converting from being egg-positive pre-treatment to egg-negative post-treatment. | 14-21 days post-treatment | |
Secondary | Egg reduction rate (ERR) against A. lumbricoides | Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs. | 14-21 days post-treatment | |
Secondary | Cure rate (CR) against Hookworm | The CR will be calculated as the proportion of participants converting from being egg-positive pre-treatment to egg-negative post-treatment. | 14-21 days post-treatment | |
Secondary | Egg reduction rate (ERR) against Hookworm | Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment to assess the corresponding ERRs. | 14-21 days post-treatment | |
Secondary | Number of participants reporting adverse events (AEs) | Participants will be monitored at the site for 3 hours following treatment for any acute AEs and reassessment will be done at 24h post-treatment. In addition, participants will be interviewed 3 and 24 hours after treatment and retrospectively at days 14-21 about the occurrence of AEs. | 3 hours, 24 hours and 14-21 days post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03261596 -
Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
|
Phase 4 | |
Completed |
NCT05538767 -
Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm
|
Phase 2 | |
Completed |
NCT03527745 -
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
|
Phase 2 | |
Active, not recruiting |
NCT04227834 -
Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education
|
N/A | |
Completed |
NCT04700423 -
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
|
Phase 2/Phase 3 | |
Completed |
NCT03172975 -
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
|
Phase 2 | |
Recruiting |
NCT06184399 -
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
|
Phase 2 | |
Completed |
NCT04726969 -
Efficacy and Safety of MOX/ALB Co-administration
|
Phase 3 | |
Completed |
NCT03995680 -
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
|
Phase 2 | |
Completed |
NCT05017194 -
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
|
Phase 2 | |
Completed |
NCT01163877 -
Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma
|
N/A |